GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » EV-to-FCF

LBPWQ (4d pharma) EV-to-FCF : 0.00 (As of Oct. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 4d pharma's Enterprise Value is $0.00 Mil. 4d pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2021 was $-34.71 Mil. Therefore, 4d pharma's EV-to-FCF for today is 0.00.

The historical rank and industry rank for 4d pharma's EV-to-FCF or its related term are showing as below:

LBPWQ' s EV-to-FCF Range Over the Past 10 Years
Min: -6.99   Med: -2.62   Max: -0.6
Current: -0.97

During the past 8 years, the highest EV-to-FCF of 4d pharma was -0.60. The lowest was -6.99. And the median was -2.62.

LBPWQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 7.88 vs LBPWQ: -0.97

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-10-31), 4d pharma's stock price is $0.0001. 4d pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.000. Therefore, 4d pharma's PE Ratio (TTM) for today is N/A.


4d pharma EV-to-FCF Historical Data

The historical data trend for 4d pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma EV-to-FCF Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial -8.76 -1.74 -2.79 -7.08 -3.60

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 - -7.08 - -3.60

Competitive Comparison of 4d pharma's EV-to-FCF

For the Biotechnology subindustry, 4d pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4d pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where 4d pharma's EV-to-FCF falls into.



4d pharma EV-to-FCF Calculation

4d pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-34.706
=0.00

4d pharma's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4d pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2021 was $-34.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4d pharma  (OTCPK:LBPWQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

4d pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/0.000
=N/A

4d pharma's share price for today is $0.0001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4d pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


4d pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of 4d pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma Headlines

From GuruFocus

4D pharma Announces Passing of Chief Financial Officer John Beck

By Business Wire Business Wire 07-26-2021

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

By Business Wire Business Wire 06-29-2021

4D pharma Announces $30 Million Credit Facility with Oxford Finance

By Business Wire Business Wire 07-29-2021

4D pharma appoints John Doyle as Chief Financial Officer

By Business Wire Business Wire 01-03-2022